Dose Finding Study of Ibrutinib Plus Lenalidomide / Rituximab in Relapsed or Refractory Mantle Cell Lymphoma (clinicaltrials.gov) - Sep 17, 2026 - P1 | N=27 | Active, not recruiting | Sponsor: Hackensack Meridian Health | Trial completion date: Jul 2026 ➔ Jan 2027
Trial completion date • Hematological Malignancies • Lymphoma • Mantle Cell Lymphoma • Neutropenia • Oncology
|